IL295292B2 - שיטות ותכשירים הקשורים לננונשאים מלאכותיים עם רפאמיצין במצב יציב סופר–רווי - Google Patents
שיטות ותכשירים הקשורים לננונשאים מלאכותיים עם רפאמיצין במצב יציב סופר–רוויInfo
- Publication number
- IL295292B2 IL295292B2 IL295292A IL29529222A IL295292B2 IL 295292 B2 IL295292 B2 IL 295292B2 IL 295292 A IL295292 A IL 295292A IL 29529222 A IL29529222 A IL 29529222A IL 295292 B2 IL295292 B2 IL 295292B2
- Authority
- IL
- Israel
- Prior art keywords
- rapamycin
- composition
- synthetic nanocarriers
- weight
- carrier material
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Cosmetics (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075866P | 2014-11-05 | 2014-11-05 | |
| US201462075864P | 2014-11-05 | 2014-11-05 | |
| PCT/US2015/059350 WO2016073799A1 (en) | 2014-11-05 | 2015-11-05 | Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL295292A IL295292A (he) | 2022-10-01 |
| IL295292B1 IL295292B1 (he) | 2024-06-01 |
| IL295292B2 true IL295292B2 (he) | 2024-10-01 |
Family
ID=54697646
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295292A IL295292B2 (he) | 2014-11-05 | 2015-11-05 | שיטות ותכשירים הקשורים לננונשאים מלאכותיים עם רפאמיצין במצב יציב סופר–רווי |
| IL296246A IL296246A (he) | 2014-11-05 | 2015-11-05 | שיטות ותכשירים הקשורים לשימוש של חומרים פעילי שטח עם hlb נמוך בייצור של ננונשאים מלאכותיים המכילים רפלוג |
| IL283699A IL283699B (he) | 2014-11-05 | 2015-11-05 | שיטות ותכשירים הקשורים לננונשאים מלאכותיים עם רפאמיצין במצב יציב סופר–רווי |
| IL251620A IL251620B (he) | 2014-11-05 | 2017-04-06 | שיטות ותכשירים הקשורים לשימוש של חומרים פעילי שטח עם hlb נמוך בייצור של ננונשאים מלאכותיים המכילים רפלוג |
| IL251622A IL251622B (he) | 2014-11-05 | 2017-04-06 | שיטות ותכשירים הקשורים לננונשאים מלאכותיים עם רפאמיצין במצב יציב סופר-רווי |
| IL280518A IL280518B (he) | 2014-11-05 | 2021-01-31 | שיטות ותכשירים הקשורים לשימוש של חומרים פעילי שטח עם hlb נמוך בייצור של ננונשאים מלאכותיים המכילים רפלוג |
| IL288609A IL288609B2 (he) | 2014-11-05 | 2021-12-02 | שיטות ותכשירים הקשורים לשימוש של חומרים פעילי שטח עם hlb נמוך בייצור של ננונשאים מלאכותיים המכילים רפלוג |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296246A IL296246A (he) | 2014-11-05 | 2015-11-05 | שיטות ותכשירים הקשורים לשימוש של חומרים פעילי שטח עם hlb נמוך בייצור של ננונשאים מלאכותיים המכילים רפלוג |
| IL283699A IL283699B (he) | 2014-11-05 | 2015-11-05 | שיטות ותכשירים הקשורים לננונשאים מלאכותיים עם רפאמיצין במצב יציב סופר–רווי |
| IL251620A IL251620B (he) | 2014-11-05 | 2017-04-06 | שיטות ותכשירים הקשורים לשימוש של חומרים פעילי שטח עם hlb נמוך בייצור של ננונשאים מלאכותיים המכילים רפלוג |
| IL251622A IL251622B (he) | 2014-11-05 | 2017-04-06 | שיטות ותכשירים הקשורים לננונשאים מלאכותיים עם רפאמיצין במצב יציב סופר-רווי |
| IL280518A IL280518B (he) | 2014-11-05 | 2021-01-31 | שיטות ותכשירים הקשורים לשימוש של חומרים פעילי שטח עם hlb נמוך בייצור של ננונשאים מלאכותיים המכילים רפלוג |
| IL288609A IL288609B2 (he) | 2014-11-05 | 2021-12-02 | שיטות ותכשירים הקשורים לשימוש של חומרים פעילי שטח עם hlb נמוך בייצור של ננונשאים מלאכותיים המכילים רפלוג |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20160128987A1 (he) |
| EP (6) | EP3834823B1 (he) |
| JP (5) | JP6912377B2 (he) |
| KR (2) | KR102656139B1 (he) |
| CN (5) | CN113244191A (he) |
| AU (4) | AU2015342969B2 (he) |
| BR (3) | BR122021025344B1 (he) |
| CA (2) | CA2966852C (he) |
| CY (1) | CY1124418T1 (he) |
| DK (4) | DK3215192T3 (he) |
| EA (2) | EA201790977A1 (he) |
| ES (4) | ES2865375T3 (he) |
| FI (2) | FI3906918T3 (he) |
| HR (1) | HRP20210098T1 (he) |
| HU (4) | HUE054894T2 (he) |
| IL (7) | IL295292B2 (he) |
| LT (1) | LT3215133T (he) |
| MX (4) | MX383295B (he) |
| PL (1) | PL3215133T3 (he) |
| PT (1) | PT3215133T (he) |
| RS (1) | RS61359B1 (he) |
| SI (1) | SI3215133T1 (he) |
| WO (2) | WO2016073798A1 (he) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6282395B2 (ja) | 2009-05-27 | 2018-02-21 | セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | 異なる放出速度の構成要素を有するナノキャリア |
| NO2575876T3 (he) | 2010-05-26 | 2018-05-05 | ||
| EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
| CN103501812A (zh) | 2011-04-29 | 2014-01-08 | 西莱克塔生物科技公司 | 用于过敏症治疗的致耐受性合成纳米载体 |
| US20130039954A1 (en) | 2011-07-29 | 2013-02-14 | Selecta Biosciences, Inc. | Control of antibody responses to synthetic nanocarriers |
| CN118370823A (zh) | 2013-05-03 | 2024-07-23 | 西莱克塔生物科技公司 | 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子 |
| WO2015025538A1 (ja) * | 2013-08-20 | 2015-02-26 | サンノプコ株式会社 | バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法 |
| WO2016037162A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector immune responses |
| US10125378B2 (en) * | 2015-02-17 | 2018-11-13 | San Nopco Ltd. | Additive for bioethanol fermentation process and method for producing bioethanol |
| US10973925B2 (en) * | 2015-04-28 | 2021-04-13 | University Of Central Florida Research Foundation Inc. | Methods and compositions for theranostic nanoparticles |
| CA3017365A1 (en) | 2016-03-11 | 2017-09-14 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
| WO2018047443A1 (ja) * | 2016-09-09 | 2018-03-15 | 花王株式会社 | ジカルボン酸結晶及びその製造方法 |
| CN109922819A (zh) | 2016-09-27 | 2019-06-21 | 西莱克塔生物科技公司 | 用于治疗癌症的重组免疫毒素 |
| KR20240015743A (ko) | 2017-01-07 | 2024-02-05 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여 |
| HUE072005T2 (hu) | 2017-03-11 | 2025-10-28 | Cartesian Therapeutics Inc | Gyulladásgátlókkal és immunszupresszánst tartalmazó szintetikus nanohordozókkal történõ kombinált kezeléssel összefüggõ eljárások és készítmények |
| MX2020003838A (es) | 2017-10-13 | 2020-08-06 | Selecta Biosciences Inc | Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral. |
| CN113412331A (zh) * | 2019-01-24 | 2021-09-17 | 世代生物公司 | 闭合端DNA(ceDNA)及其在减少与基因或核酸疗法相关的免疫应答的方法中的用途 |
| CN114126666A (zh) | 2019-04-28 | 2022-03-01 | 西莱克塔生物科技公司 | 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法 |
| CN114206396A (zh) | 2019-05-28 | 2022-03-18 | 西莱克塔生物科技公司 | 用于减弱抗病毒转移载体免疫应答的方法和组合物 |
| CN114207440A (zh) | 2019-06-04 | 2022-03-18 | 西莱克塔生物科技公司 | 聚乙二醇化尿酸酶的制剂和剂量 |
| US20210154324A1 (en) * | 2019-10-21 | 2021-05-27 | Selecta Biosciences, Inc. | Methods and compositions for treating liver diseases and disorders |
| JP2023501457A (ja) | 2019-11-08 | 2023-01-18 | セレクタ バイオサイエンシーズ インコーポレーテッド | ペグ化ウリカーゼの処方物および用量 |
| WO2021174013A1 (en) | 2020-02-26 | 2021-09-02 | Selecta Biosciences, Inc. | Methods and compositions using synthetic nanocarriers comprising immunosuppressant |
| KR20220152263A (ko) * | 2020-03-11 | 2022-11-15 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체와 관련된 방법 및 조성물 |
| AU2020442489A1 (en) * | 2020-04-14 | 2022-11-10 | Selecta Biosciences, Inc. | Methods and compositions for inducing autophagy |
| AU2021373792A1 (en) | 2020-11-04 | 2023-06-08 | Selecta Biosciences, Inc. | Compositions for reducing immune responses against immunoglobulin proteases |
| AU2022206197A1 (en) | 2021-01-05 | 2023-07-13 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| KR102304785B1 (ko) | 2021-03-26 | 2021-09-24 | (주)진성티앤피 | 정밀광학기기의 부품 제조 방법 |
| JP2024514577A (ja) | 2021-04-09 | 2024-04-02 | セレクタ バイオサイエンシーズ インコーポレーテッド | 免疫寛容を増強するために高親和性ｉｌ－２受容体アゴニストと組み合わせて免疫抑制剤を含む合成ナノキャリア |
| WO2022221529A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
| JP2024539646A (ja) | 2021-10-12 | 2024-10-29 | カーティザン セラピューティクス，インコーポレーテッド | ウイルスベクター投薬プロトコル |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| JP2024545594A (ja) | 2021-11-14 | 2024-12-10 | カーティザン セラピューティクス，インコーポレーテッド | ウイルスベクターでの複数回投薬 |
| WO2023133319A1 (en) | 2022-01-10 | 2023-07-13 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
| US20230322884A1 (en) | 2022-03-09 | 2023-10-12 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| WO2023196566A1 (en) | 2022-04-08 | 2023-10-12 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
| EP4568750A1 (en) | 2022-08-11 | 2025-06-18 | Cartesian Therapeutics, Inc. | Compositions and methods related to immunoglobulin proteases and fusions thereof |
| WO2024107889A1 (en) | 2022-11-15 | 2024-05-23 | Selecta Biosciences, Inc. | Compositions and methods for treating primary biliary cholangitis |
| WO2024229380A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases |
| WO2024229370A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Compositions and methods for treating gvhd |
| WO2024229350A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes |
| WO2024229432A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
| TWI877967B (zh) * | 2023-12-28 | 2025-03-21 | 訊聯生物科技股份有限公司 | 包含小分子核糖核酸及奈米載體之組合物、包含其的醫藥組成物及其用途 |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
| US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
| US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
| US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
| US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
| US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
| AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| US7288266B2 (en) | 1996-08-19 | 2007-10-30 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
| US6187335B1 (en) | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
| US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| JP2002521423A (ja) | 1998-07-31 | 2002-07-16 | コリア インスティチュート オブ サイエンス アンド テクノロージ | 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子 |
| EP1107783B1 (en) * | 1998-09-01 | 2006-04-05 | ELAN CORPORATION, Plc | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
| CN1406140A (zh) | 2000-02-28 | 2003-03-26 | 吉倪塞思公司 | 纳米胶囊包封系统与方法 |
| US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
| EP1530456A2 (en) | 2002-08-23 | 2005-05-18 | Munich Biotech AG | Non-vesicular cationic lipid formulations |
| CN1886100A (zh) * | 2003-11-14 | 2006-12-27 | 阿尔萨公司 | 基于表面活性剂的凝胶作为可注射的持续药物递送载体 |
| US20050260260A1 (en) | 2004-05-19 | 2005-11-24 | Edward Kisak | Liposome compositions for the delivery of macromolecules |
| CN101291658B (zh) * | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
| US8414910B2 (en) * | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| EP2620157A3 (en) | 2007-10-12 | 2013-10-16 | Massachusetts Institute of Technology | Vaccine nanotechnology |
| WO2010005726A2 (en) * | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| EA020954B1 (ru) * | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| ES2776126T3 (es) * | 2008-12-15 | 2020-07-29 | Pfizer | Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos |
| KR101267813B1 (ko) * | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
| WO2012035074A1 (en) * | 2010-09-14 | 2012-03-22 | Nanologica Ab | Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients |
| WO2012059936A1 (en) * | 2010-11-03 | 2012-05-10 | Padma Venkitachalam Devarajan | Pharmaceutical compositions for colloidal drug delivery |
| CN103501812A (zh) * | 2011-04-29 | 2014-01-08 | 西莱克塔生物科技公司 | 用于过敏症治疗的致耐受性合成纳米载体 |
| CN102793674B (zh) * | 2011-05-26 | 2014-11-26 | 澳门科技大学 | 一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用 |
| WO2013056132A2 (en) | 2011-10-14 | 2013-04-18 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| TWI439288B (zh) * | 2012-10-05 | 2014-06-01 | Univ China Medical | 藥用載體及其製備方法與用途 |
| CN102871966B (zh) * | 2012-10-19 | 2013-11-20 | 东南大学 | 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法 |
-
2015
- 2015-11-05 ES ES15857076T patent/ES2865375T3/es active Active
- 2015-11-05 EP EP20204014.3A patent/EP3834823B1/en active Active
- 2015-11-05 LT LTEP15798601.9T patent/LT3215133T/lt unknown
- 2015-11-05 AU AU2015342969A patent/AU2015342969B2/en active Active
- 2015-11-05 US US14/934,135 patent/US20160128987A1/en not_active Abandoned
- 2015-11-05 ES ES20204014T patent/ES2977158T3/es active Active
- 2015-11-05 MX MX2017005903A patent/MX383295B/es unknown
- 2015-11-05 HU HUE15857076A patent/HUE054894T2/hu unknown
- 2015-11-05 CN CN202110403075.4A patent/CN113244191A/zh active Pending
- 2015-11-05 EP EP15857076.2A patent/EP3215192B1/en active Active
- 2015-11-05 FI FIEP21156943.9T patent/FI3906918T3/fi active
- 2015-11-05 IL IL295292A patent/IL295292B2/he unknown
- 2015-11-05 HR HRP20210098TT patent/HRP20210098T1/hr unknown
- 2015-11-05 EA EA201790977A patent/EA201790977A1/ru unknown
- 2015-11-05 EP EP15798601.9A patent/EP3215133B1/en active Active
- 2015-11-05 IL IL296246A patent/IL296246A/he unknown
- 2015-11-05 JP JP2017524450A patent/JP6912377B2/ja active Active
- 2015-11-05 JP JP2017524451A patent/JP7218089B2/ja active Active
- 2015-11-05 BR BR122021025344-7A patent/BR122021025344B1/pt active IP Right Grant
- 2015-11-05 US US14/934,132 patent/US20160128986A1/en active Pending
- 2015-11-05 RS RS20210097A patent/RS61359B1/sr unknown
- 2015-11-05 DK DK15857076.2T patent/DK3215192T3/da active
- 2015-11-05 CN CN202210754468.4A patent/CN115212186A/zh active Pending
- 2015-11-05 HU HUE15798601A patent/HUE053094T2/hu unknown
- 2015-11-05 BR BR112017008499-6A patent/BR112017008499B1/pt active IP Right Grant
- 2015-11-05 DK DK21156943.9T patent/DK3906918T3/da active
- 2015-11-05 MX MX2017005904A patent/MX386982B/es unknown
- 2015-11-05 EP EP23220853.8A patent/EP4360633A3/en not_active Withdrawn
- 2015-11-05 CN CN201580060789.2A patent/CN107072965B/zh active Active
- 2015-11-05 EP EP21156943.9A patent/EP3906918B1/en active Active
- 2015-11-05 KR KR1020177014830A patent/KR102656139B1/ko active Active
- 2015-11-05 BR BR112017008720A patent/BR112017008720A2/pt not_active Application Discontinuation
- 2015-11-05 ES ES15798601T patent/ES2846809T3/es active Active
- 2015-11-05 HU HUE21156943A patent/HUE067697T2/hu unknown
- 2015-11-05 KR KR1020177014831A patent/KR102601922B1/ko active Active
- 2015-11-05 EA EA201790978A patent/EA201790978A1/ru unknown
- 2015-11-05 WO PCT/US2015/059349 patent/WO2016073798A1/en not_active Ceased
- 2015-11-05 HU HUE20204014A patent/HUE066099T2/hu unknown
- 2015-11-05 PL PL15798601T patent/PL3215133T3/pl unknown
- 2015-11-05 IL IL283699A patent/IL283699B/he unknown
- 2015-11-05 CN CN201580059855.4A patent/CN107072964A/zh active Pending
- 2015-11-05 FI FIEP20204014.3T patent/FI3834823T3/fi active
- 2015-11-05 AU AU2015342968A patent/AU2015342968B2/en active Active
- 2015-11-05 PT PT157986019T patent/PT3215133T/pt unknown
- 2015-11-05 EP EP23220845.4A patent/EP4356910A3/en not_active Withdrawn
- 2015-11-05 SI SI201531494T patent/SI3215133T1/sl unknown
- 2015-11-05 CN CN202210754573.8A patent/CN115212187A/zh active Pending
- 2015-11-05 ES ES21156943T patent/ES2977259T3/es active Active
- 2015-11-05 CA CA2966852A patent/CA2966852C/en active Active
- 2015-11-05 DK DK15798601.9T patent/DK3215133T3/da active
- 2015-11-05 CA CA2966850A patent/CA2966850C/en active Active
- 2015-11-05 WO PCT/US2015/059350 patent/WO2016073799A1/en not_active Ceased
- 2015-11-05 DK DK20204014.3T patent/DK3834823T3/da active
-
2017
- 2017-04-06 IL IL251620A patent/IL251620B/he active IP Right Grant
- 2017-04-06 IL IL251622A patent/IL251622B/he active IP Right Grant
- 2017-05-04 MX MX2021006698A patent/MX2021006698A/es unknown
- 2017-05-04 MX MX2021012273A patent/MX2021012273A/es unknown
-
2021
- 2021-01-27 CY CY20211100063T patent/CY1124418T1/el unknown
- 2021-01-31 IL IL280518A patent/IL280518B/he unknown
- 2021-05-10 JP JP2021080003A patent/JP2021143180A/ja active Pending
- 2021-07-27 AU AU2021209202A patent/AU2021209202B2/en active Active
- 2021-07-27 AU AU2021209204A patent/AU2021209204A1/en not_active Abandoned
- 2021-12-02 IL IL288609A patent/IL288609B2/he unknown
-
2022
- 2022-09-01 JP JP2022139392A patent/JP2022173236A/ja active Pending
-
2023
- 2023-07-03 JP JP2023109379A patent/JP2023169893A/ja active Pending
-
2024
- 2024-10-21 US US18/921,868 patent/US20250152561A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250152561A1 (en) | Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state | |
| US20210308058A1 (en) | Methods and compositions related to synthetic nanocarriers |